Addex adx71149 epilepsy phase 2 study completes recruitment of patients

Top line results expected in q2 2024 ad hoc announcement pursuant to art. 53 lr geneva, switzerland, november 14, 2023 - addex therapeutics (six and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the last patient has been randomized in cohort 2 of the adx71149 (jnj-40411813) phase 2 epilepsy clinical study.
ADXN Ratings Summary
ADXN Quant Ranking